title: Modification of natural immunity in mice by imipenem/cilastatin.
abstract: The imipenem/cilastatin constitutes a broad spectrum beta-lactam antibiotic formulation, especially used in pre and post-operatory treatments for transplanted or drug-immunosuppresed patients. The effect of the dose and the duration of the treatment with imipenem/cilastatin on some parameters of natural immunity in BALB/c mice were examined. The treatment by intraperitoneal route with 1 or 2 g/70 kg/day during 7 days did not alter significantly the parameters tested, whereas the greater dose used (4 g/70 kg/day) had an inhibitory effect on peritoneal cell counts and phagocytic activity, as well as it caused an increase on IL-1 production and natural killer activity. The greater stimulating effect of innate immunity was obtained with the lowest imipenem/cilastatin dose used (0.5 g/70 kg/day). Since this antibiotic apparently does not impair the studied innate immune responses at 1 or 2 g/70 kg/day, it seems to be especially suited for the therapy of systemic bacterial infections in immunocompromised patients.
authors.affiliation: Department of Health Sciences, University of Jaén, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Ortega
authors.forename: M A
authors.initials: MA
authors.lastname: de Pablo
authors.forename: A M
authors.initials: AM
authors.lastname: Gallego
authors.forename: C
authors.initials: C
authors.lastname: Alvarez
authors.forename: P L
authors.initials: PL
authors.lastname: Pancorbo
authors.forename: A
authors.initials: A
authors.lastname: Ruiz-Bravo
authors.forename: G A
authors.initials: GA
authors.lastname: de Cienfuegos
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002452:Cell Count / Q000187:drug effects; D015377:Cilastatin / Q000494:pharmacology; D000077728:Cilastatin, Imipenem Drug Combination; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D015378:Imipenem / Q000494:pharmacology; D007113:Immunity, Innate / Q000187:drug effects*; D007376:Interleukin-2 / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D017737:Macrophages, Peritoneal / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010529:Peritoneal Cavity / Q000166:cytology; D010587:Phagocytosis / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D007376:Interleukin-2; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination